The Full Wiki

More info on Technetium (99mTc) fanolesomab

Technetium (99mTc) fanolesomab: Wikis


Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.

Encyclopedia

From Wikipedia, the free encyclopedia

Technetium (99mTc) fanolesomab ?
Monoclonal antibody
Source Mouse
Target CD15
Identifiers
CAS number 225239-31-6
ATC code none
PubChem  ?
Chemical data
Formula  ?
Mol. mass  ?
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.  ?
Legal status
Routes Intravenous

Technetium (99mTc) fanolesomab (trade name NeutroSpec, manufactured by Palatin Technologies) is a mouse monoclonal antibody formerly used to aid in the diagnosis of appendicitis. It is labeled with a radioisotope, technetium-99m (99mTc).

Contents

History and use

NeutroSpec was approved by the U.S. Food and Drug Administration (FDA) in June 2004 for imaging of patients with symptoms of appendicitis. It consisted of an intact murine (mouse) IgM monoclonal antibody against human CD15, labeled with technetium-99m so as to be visible on a gamma camera image. Since anti-CD15 antibodies bind selectively to white blood cells such as neutrophils, it could be used to localize the site of an infection.

Deaths and associated recall

The FDA received reports from Palatin of 2 deaths and 15 life-threatening adverse events in patients who had received NeutroSpec.

These events occurred within minutes of administration of NeutroSpec and included shortness of breath, low blood pressure, and cardiopulmonary arrest. Affected patients required resuscitation with intravenous fluids, blood pressure support, and oxygen. Most, but not all, of the patients who experienced these events had existing cardiac and/or pulmonary conditions that may have placed them at higher risk for these adverse events. A review of all post-marketing reports showed an additional 46 patients who experienced adverse events that were similar but less severe. All of the reactions occurred immediately after NeutroSpec was administered.[1]

Marketing of the product was suspended in December 2005.

References

  • Walker, R, et al. Future Microbiol 2007; 2: 527-554
  • Kipper SL, et al. J Nucl Med 2000; 41: 449-455
  • Rypins EB, et al. Ann Surg 2002; 235: 232-239
  • Palestro CJ, et al. Radiology 2002; 223: 758-764
  • Love C, et al. Q J Nucl Med Mol Imaging 2006; 50: 113-120

External links








Got something to say? Make a comment.
Your name
Your email address
Message